Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

@article{Prasad2011InhibitionOP,
  title={Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.},
  author={Gautam Prasad and Theo L Sottero and Xiaodong Yang and Sabine Mueller and C. David James and William Andrew Weiss and Mei-Yin C Polley and Tomoko Ozawa and Mitchel S. Berger and Dana T. Aftab and Michael D. Prados and Daphne Adele Haas-Kogan},
  journal={Neuro-oncology},
  year={2011},
  volume={13 4},
  pages={384-92}
}
Due to its molecular heterogeneity and infiltrative nature, glioblastoma multiforme (GBM) is notoriously resistant to traditional and experimental therapeutics. To overcome these hurdles, targeted agents have been combined with conventional therapy. We evaluated the preclinical potential of a novel, orally bioavailable PI3K/mTOR dual inhibitor (XL765) in in vitro and in vivo studies. In vivo serially passaged human GBM xenografts that are more genetically stable than GBM cell lines in culture… CONTINUE READING